More than 3 million Americans have been diagnosed with emphysema, and millions more may have it – along with related chronic obstructive pulmonary disease (COPD) – without knowing it. According to the CDC, emphysema is a chronic, progressive lung disease that permanently destroys the tiny air sacs in the lungs, making it increasingly difficult to breathe. It falls under the broader umbrella of COPD – a leading cause of death and disability in the United States – and is overwhelmingly caused by cigarette smoking. While the damage already done cannot be undone, understanding emphysema opens the door to treatments that slow progression and improve quality of life. For an overview of chronic conditions, visit our medical conditions guide.
The essentials: Emphysema is a form of COPD in which the lungs’ air sacs are permanently destroyed, so it can’t be reversed – but it can be managed. Quitting smoking is the single most important treatment and the only one proven to slow the accelerated decline in lung function. Care centers on inhaled bronchodilators (and inhaled steroids for some patients), pulmonary rehabilitation, oxygen when levels are low, staying current on vaccines, and good nutrition. Everyone diagnosed should be tested once for alpha-1 antitrypsin deficiency. All medications here are clinician-directed – this article contains no dosing and is not a substitute for your doctor’s advice.
A COPD/emphysema exacerbation can become life-threatening. Call 911 or get emergency help now if you have severe shortness of breath, cannot speak in full sentences, have bluish or gray lips or fingernails, feel confused or drowsy, have a high fever, are coughing up blood, or have chest pain. Do not wait it out. Seek prompt (same-day) medical care for worsening breathlessness, more coughing, or a change in the color, thickness, or amount of your phlegm, especially if your rescue inhaler isn’t helping. If you use home oxygen, an exacerbation still needs medical evaluation – do not simply turn your oxygen up on your own without guidance.
What Is Emphysema?
In healthy lungs, millions of tiny air sacs called alveoli cluster at the ends of the smallest airways like grapes on a vine. These thin-walled structures are where the essential work of breathing happens – oxygen passes from inhaled air into the bloodstream, and carbon dioxide passes from the blood into the air to be exhaled. Emphysema destroys the walls between these alveoli, merging small, efficient air sacs into larger, less effective ones.
This destruction has two critical consequences. First, the surface area available for gas exchange shrinks dramatically. Second, the loss of the alveolar walls eliminates the structural support that normally holds the small airways open. Without this support, the airways collapse during exhalation, trapping stale, carbon dioxide-rich air in the lungs. This air trapping is what gives many emphysema patients a barrel-shaped chest and their characteristic struggle to exhale completely.
The NHLBI classifies emphysema as one of the two main conditions under the COPD umbrella, alongside chronic bronchitis. In practice, most people with COPD have elements of both, though one may predominate. Emphysema tends to dominate in patients with more significant shortness of breath and air trapping, while chronic bronchitis features more prominently in those with persistent cough and mucus production.
Causes
Cigarette smoking is the cause of emphysema in the large majority of cases – commonly cited as around 85-90%. Tobacco smoke contains thousands of chemicals that trigger a destructive inflammatory response in the lungs. Immune cells called neutrophils and macrophages are recruited to the airways and release enzymes (particularly elastase) that break down elastin – the protein responsible for the alveoli’s elastic recoil. Over decades, this continuous enzymatic assault progressively destroys alveolar walls.
Alpha-1 antitrypsin (AAT) deficiency is the primary inherited, non-smoking cause of emphysema. Alpha-1 antitrypsin is a protein produced by the liver that normally protects the lungs from elastase damage. People with AAT deficiency lack adequate levels of this protective protein, leaving their lungs vulnerable to damage from even normal inflammatory processes. AAT deficiency affects roughly 1 in 2,000-5,000 people of European descent and can cause emphysema in people as young as their 30s or 40s, especially if they also smoke. It is under-recognized, which is why testing everyone with emphysema at least once is now standard advice.
Other contributing factors include long-term exposure to secondhand smoke, occupational dust and chemicals (coal dust, grain dust, silica, chemical fumes), indoor and outdoor air pollution, and a history of recurrent or severe respiratory infections in childhood. According to the Mayo Clinic, marijuana smoke may also contribute, though research is still limited, and there is growing interest in whether long-term vaping affects lung health, an area still under study. Aging itself causes some loss of alveolar structure, but this is a minor contributor compared with smoking.
Symptoms
Emphysema develops insidiously over years, and early symptoms are easy to dismiss. The primary symptom is progressive shortness of breath – initially noticeable only during vigorous exercise, then during moderate activity like climbing stairs, and eventually during simple daily tasks like dressing or bathing. This gradual onset means many people unconsciously adapt by reducing their activity levels, mistaking the decline for normal aging.
Other common symptoms include a chronic, often non-productive cough (or one that produces only small amounts of clear sputum), wheezing, chest tightness, and a sensation of not being able to get a full breath. As the disease advances, patients may develop a barrel-shaped chest (from chronic air trapping), use of accessory muscles for breathing (neck and shoulder muscles working visibly with each breath), pursed-lip breathing (an instinctive technique that helps keep airways open during exhalation), and unintentional weight loss.
In advanced emphysema, reduced oxygen levels can cause a bluish tint to the lips and fingernails (cyanosis), and chronic low oxygen can lead to secondary complications including pulmonary hypertension (high blood pressure in the lung arteries) and right-sided heart failure (cor pulmonale). The Cleveland Clinic notes that people with emphysema were historically described as “pink puffers” because of their labored breathing and relatively maintained oxygen in earlier stages, in contrast to the “blue bloaters” of chronic bronchitis – though in reality most patients don’t fit neatly into either category.
Diagnosis
Spirometry is the essential diagnostic test for emphysema and COPD. It measures how much air you can forcefully exhale in one second (FEV1) and the total amount you can exhale (FVC). A reduced FEV1/FVC ratio (below 0.70) that doesn’t fully normalize with a bronchodilator indicates fixed airflow obstruction consistent with emphysema/COPD. The severity of airflow limitation is graded using the GOLD framework based on FEV1 percentage of predicted, and clinicians also weigh your symptoms and exacerbation history when planning treatment.
CT scanning of the chest can directly visualize the destruction of alveolar walls, showing areas of low attenuation (dark areas where lung tissue has been lost). High-resolution CT is particularly useful for characterizing the distribution and severity of emphysema and for surgical or valve planning. Chest X-ray may show hyperinflated lungs and a flattened diaphragm but is less sensitive than CT for detecting early emphysema.
Pulmonary function tests (PFTs) beyond basic spirometry – including lung volumes and diffusing capacity (DLCO) – help characterize the physiological impact. Increased total lung capacity and residual volume reflect air trapping, while a reduced DLCO reflects loss of gas-exchanging surface area. Alpha-1 antitrypsin testing should be performed at least once in every person diagnosed with emphysema or COPD. Arterial blood gas analysis and pulse oximetry assess oxygenation. According to the NHLBI, earlier diagnosis through spirometry in at-risk individuals allows earlier intervention and better outcomes.
Treatment: Smoking Cessation
Quitting smoking is the single most important treatment for emphysema – the only intervention proven to slow the accelerated decline in lung function. While quitting can’t reverse existing damage, it returns the rate of lung function decline toward the slower, age-related rate experienced by non-smokers. The CDC emphasizes that it’s never too late to quit – benefits occur at any age and any stage of disease.
Effective cessation aids include nicotine replacement therapy (patches, gum, lozenges, inhaler, nasal spray), varenicline, and bupropion. Combining medication with behavioral support (counseling, quit-lines such as 1-800-QUIT-NOW, apps, or support groups) produces the highest success rates. Any medication should be chosen with your clinician. Most smokers require multiple quit attempts – each one provides valuable experience and brings you closer to permanent cessation. Avoiding secondhand smoke and other lung irritants matters too.
Treatment: Medications
Bronchodilators are the mainstay of drug treatment. Long-acting muscarinic antagonists (LAMAs) such as tiotropium and long-acting beta-agonists (LABAs) such as salmeterol and formoterol are used as daily maintenance therapy; they relax airway muscles, reduce air trapping, and improve exercise capacity. Short-acting bronchodilators (albuterol, ipratropium) provide quick relief for acute symptoms.
Inhaled corticosteroids (ICS) are added for selected patients, particularly those with frequent exacerbations, features of asthma-COPD overlap, or elevated blood eosinophil counts. Triple-therapy inhalers combining a LAMA, LABA, and ICS in one device can reduce exacerbations in appropriate patients. The Mayo Clinic stresses that inhaler technique is critical – if you’re not using your inhaler correctly, you’re not getting the full benefit. Ask your provider or pharmacist to watch your technique. Do not start or stop any inhaler on your own, and this guide intentionally includes no dosing, because the right regimen is individualized by your prescriber.
Roflumilast, an oral phosphodiesterase-4 inhibitor, may be added for patients with severe emphysema/COPD and frequent exacerbations despite inhaler therapy. Long-term azithromycin can reduce exacerbation frequency in selected patients. Oral corticosteroids and, when appropriate, antibiotics are used for acute exacerbations and should be used for the shortest effective course because of side effects with repeated or prolonged use. All of these are prescriber-directed decisions.
Treatment: Non-Pharmacological Approaches
Pulmonary Rehabilitation
Pulmonary rehabilitation is one of the most effective interventions for emphysema, consistently producing improvements in exercise capacity, breathlessness, and quality of life that often exceed what medications achieve. Programs typically run six to twelve weeks and include supervised exercise training, education, breathing techniques (pursed-lip and diaphragmatic breathing), nutritional counseling, and psychosocial support. Major guidelines and Cochrane reviews recommend pulmonary rehabilitation for patients with emphysema who remain symptomatic despite optimal medical therapy, and it is especially valuable after a hospitalization for a flare-up.
Oxygen Therapy
Long-term supplemental oxygen – used at least 15 hours per day – improves survival in patients with severe emphysema and chronically low blood oxygen (for example, a resting oxygen level below defined thresholds confirmed by testing). It can also reduce strain on the heart, improve exercise tolerance, and support cognitive function. Modern portable oxygen concentrators are smaller and lighter than ever, helping patients stay mobile. Oxygen is prescribed and titrated by your clinician based on measured levels – it is a medical therapy, not something to adjust freely. Understanding healthcare costs is relevant when managing the ongoing expenses of oxygen equipment and supplies.
Surgical and Bronchoscopic Options
Lung volume reduction surgery (LVRS) removes the most severely damaged portions of the lungs, allowing healthier tissue to expand and the diaphragm to work more effectively. Landmark trial evidence (the NETT study) showed that LVRS improves exercise capacity and survival in carefully selected patients with upper-lobe-predominant emphysema and low baseline exercise capacity.
Bronchoscopic lung volume reduction using endobronchial valves (such as FDA-approved one-way valve systems) is a less invasive alternative for patients with severe emphysema, intact fissures between lung lobes, and significant hyperinflation. The valves prevent air from entering the most damaged lobe, allowing it to deflate and giving healthier tissue room to function. Lung transplantation remains an option for carefully selected patients with end-stage emphysema who meet eligibility criteria. All of these require evaluation at specialized centers.
Vaccinations and Preventing Exacerbations
Acute exacerbations – episodes of worsening symptoms beyond normal day-to-day variation – accelerate lung function decline, reduce quality of life, and increase the risk of hospitalization and death. Prevention is critical. Take maintenance medications consistently, and stay current on recommended vaccines. Based on CDC/ACIP guidance, adults with emphysema/COPD should generally receive the annual influenza vaccine, COVID-19 vaccination as recommended, pneumococcal vaccination, and the RSV vaccine (RSV vaccination is recommended for older adults and for younger adults with chronic lung disease – confirm current age and eligibility criteria with your clinician). Staying up to date on Tdap and other routine vaccines is also wise. Practice good hand hygiene, avoid crowds during respiratory-illness season when possible, and monitor local air quality.
Know the early warning signs of an exacerbation: increased shortness of breath, more coughing, a change in sputum color, volume, or thickness, fever, or worsening fatigue. Having a written COPD action plan – developed with your clinician – that specifies when to increase your rescue inhaler, when to start prescribed oral steroids or antibiotics, and when to seek emergency care helps you respond quickly and may prevent hospitalization. Review the emergency warning box above so you know when a flare-up has crossed into an emergency.
Frequently Asked Questions
Can emphysema be reversed?
No. The alveolar destruction that defines emphysema is permanent – the body cannot regrow these structures. However, quitting smoking stops further accelerated decline, medications can optimize remaining lung function, and pulmonary rehabilitation can dramatically improve your ability to use the lung capacity you have. Many people experience meaningful improvement in symptoms and quality of life even though the underlying damage persists.
How long can you live with emphysema?
Life expectancy depends on severity at diagnosis, whether you keep smoking, how well you respond to treatment, and your overall health. Many people with mild-to-moderate emphysema live for decades after diagnosis, particularly if they quit smoking and stay active. Clinicians sometimes use tools like the BODE index (body mass index, airflow obstruction, dyspnea, exercise capacity) to help estimate prognosis, but individual outcomes vary widely.
Is emphysema the same as COPD?
Emphysema is one of the two main conditions under the COPD umbrella (the other being chronic bronchitis). Most people with COPD have features of both. COPD is the broader clinical term; emphysema specifically refers to the destruction of alveolar walls and air trapping. When your doctor says “COPD,” they may mean emphysema, chronic bronchitis, or both.
Can non-smokers get emphysema?
Yes, though it’s less common. Alpha-1 antitrypsin deficiency is the best-known cause of emphysema in non-smokers. Long-term exposure to secondhand smoke, occupational dusts and chemicals, indoor and outdoor air pollution, and a history of severe childhood respiratory infections can also contribute. If you develop emphysema without a significant smoking history, AAT deficiency testing is essential.
Does emphysema qualify for disability?
Severe emphysema can qualify for Social Security disability benefits if your pulmonary function tests meet specific criteria (generally an FEV1 at or below certain thresholds based on height) or if you can demonstrate that your condition prevents any substantial gainful activity. Documentation from your pulmonologist – including spirometry, arterial blood gas results, and exercise testing – supports disability applications. Criteria are set by the Social Security Administration and are updated periodically.
Breathing Better With Emphysema
Emphysema changes the way you breathe, but it doesn’t have to define the way you live. Quit smoking if you haven’t already – this is non-negotiable and the most powerful thing you can do. Engage fully in pulmonary rehabilitation; the evidence that it helps is unequivocal. Take your medications as prescribed, learn and practice breathing techniques, stay as physically active as your lungs allow, and maintain good nutrition (being underweight is a significant risk factor for poor outcomes in emphysema).
Plan ahead for exacerbations – keep an action plan visible, stay current on vaccinations, know when to escalate care, and don’t wait too long to seek help. And while the damage to your lungs cannot be reversed, every positive step you take preserves what you have and maximizes what it can do. Living well with emphysema means working with your body’s remaining capacity, in close partnership with your care team, rather than giving up on it.
Medical disclaimer: This article is general education, not medical advice, and is not a substitute for care from a qualified clinician. Emphysema/COPD treatment must be individualized. Do not start, stop, or change any medication – including inhalers, steroids, or oxygen – on your own, and do not use any dose you read online. A severe flare-up is a medical emergency: severe breathlessness, bluish lips, confusion, high fever, or coughing up blood means call 911 or seek urgent care.
Sources
- Centers for Disease Control and Prevention (CDC) – COPD
- National Heart, Lung, and Blood Institute (NHLBI) – COPD
- Mayo Clinic – Emphysema: symptoms, causes, and treatment
- Global Initiative for Chronic Obstructive Lung Disease (GOLD) – 2025/2026 Report
- American Lung Association – Emphysema and COPD
- CDC / ACIP – Adult immunization schedule (influenza, COVID-19, pneumococcal, RSV)
- Cleveland Clinic – Emphysema